The chronic nature and associated complications of nonhealing wounds have led to the emergence of nanotechnology-based therapies that aim at facilitating the healing process and ultimately repairing the injured tissue. A number of engineered nanotechnologies have been proposed demonstrating unique properties and multiple functions that address specific problems associated with wound repair mechanisms. In this outlook, we highlight the most recently developed nanotechnology-based therapeutic agents and assess the viability and efficacy of each treatment, with emphasis on chronic cutaneous wounds. Herein we explore the unmet needs and future directions of current technologies, while discussing promising strategies that can advance the wound-healing field. W ound healing in skin is an evolutionarily conserved, highly coordinated, spatiotemporally regulated process. It occurs over the sequential yet overlapping phases of hemostasis, inflammation, proliferation, and remodeling.
ABSTRACT:
The chronic nature and associated complications of nonhealing wounds have led to the emergence of nanotechnology-based therapies that aim at facilitating the healing process and ultimately repairing the injured tissue. A number of engineered nanotechnologies have been proposed demonstrating unique properties and multiple functions that address specific problems associated with wound repair mechanisms. In this outlook, we highlight the most recently developed nanotechnology-based therapeutic agents and assess the viability and efficacy of each treatment, with emphasis on chronic cutaneous wounds. Herein we explore the unmet needs and future directions of current technologies, while discussing promising strategies that can advance the wound-healing field.
W ound healing in skin is an evolutionarily conserved, highly coordinated, spatiotemporally regulated process. It occurs over the sequential yet overlapping phases of hemostasis, inflammation, proliferation, and remodeling. 1, 2 The phases of the cutaneous wound healing are executed by coordinated action of multiple cell types including keratinocytes, fibroblasts, and immune, endothelial, and progenitor cells ( Figure 1 ). 1, 3 These steps involve multiple cellular and molecular events tightly controlled by numerous growth factors, chemokines, and cytokines. In addition, the dynamic relationship between skin and microbiome is another major contributor to the outcome of this process. Signaling networks involving the interleukin (IL) family and growth factors are required to coordinate cell−cell and cell−extracellular matrix (ECM) interactions essential to fully heal a wound, with imbalances leading to a nonhealing, chronic wound. 1, 4, 5 Chronic wounds are characterized by unresolved inflammation, nonmigratory epidermis, impaired fibroblast function and ECM deposition, decreased angiogenesis, increased levels of proteases, and bacterial colonization and/or infection. 4,6−10 The incidence of chronic wounds (venous, diabetic foot, or pressure ulcers) is on the rise, reaching epidemic proportions, which justifies the increased interest in finding more efficient therapies.
1 Nanotechnology-based diagnostics and treatment approaches offer an excellent opportunity to target the complexity of the normal wound-healing process, cell type specificity, and plethora of regulating molecules as well as pathophysiology of chronic wounds. Conceptually, cutaneous wound healing has major advantages for use of nanotherapeutics. It requires topical delivery, can be multifactorial and cell-type specific, and the therapeutic agent is used for a limited time or until the wound has healed.
To date, there are only four FDA-approved therapies for chronic cutaneous wounds, including a bioengineered human skin equivalent, two dermal substitutes, and recombinant human platelet derived growth factor (rhPDGF). 11−15 Human skin equivalent and dermal substitutes have been suggested to act as a "smart" biomaterial by interacting with the wound environment to promote a healthy healing process. PDGF exhibits beneficial effects during wound healing by stimulating chemotaxis of neutrophils, macrophages, fibroblasts, and smooth muscle cells. 16, 17 However, 44 to 70% of treated patients affected with chronic ulcers remain unhealed, even in the clinical trials that lead to FDA approval. 12, 18, 19 Better understanding of the wound-healing process has also contributed to the emergence of contemporary dressing-based therapies (Table 1) . 20, 21 Thus, modern dressings were custom designed to provide the beneficial microenvironment for successful healing by controlling wound moisture and absorbing excess exudate. 22 Active dressings may locally alter the wound's biochemical environment by targeting bacterial load and excessive protease levels, or providing exogenous collagen matrices which serve as a scaffold for tissue ingrowth when endogenous collagen is disrupted by the proteolytic wound environment (Table 1) . 23, 24 Despite trials demonstrating the benefits of improved dressings incorporating recombinant growth factors and cells, many of the modalities used in clinical practice are based on safety data and clinical experience rather than evidence of efficacy. 25 The failure of many novel approaches in delivering specific outcomes such as wound closure, control of fluid loss, and exhibiting properties such as durability, elasticity, and histocompatibility has led to the introduction of numerous nanotechnological advances. 32 Furthermore, the field of chronic wounds is in dire need of robust, more efficacious treatments that are able to address a dysfunctional healing process at multiple cellular levels. These findings underscore the need for development and implementation of novel nanotechnologydriven therapies. Nanotherapeutic approaches that employ materials engineered with at least one dimension within the nanoscale (1−100 nm) were pioneered to efficiently control wound healing and minimize any possible complication that might surface during this process. 32, 33 The major advantage of nanomaterials over their bulk counterparts is the versatility and tunability of the nanomaterial's physicochemical properties (e.g., hydrophobicity, charge, size). 20 Furthermore, the high surface area to volume ratio endows nanostructures with unique features. 32 For example, nanoscale particles provide for a high probability of interaction with the biological target and an enhanced penetration into the wound site. 33 As a result, nanoparticles have an ability to deliver a sustained and controlled release of therapeutics that results in an accelerated healing process. 23 In this outlook, we highlight the most recent advances in nanotechnology that contributed to a paradigm shift in woundhealing therapeutics. We will briefly introduce the newly developed nanomaterials, nanoengineering processes, and gene, growth factor, The incidence of chronic wounds (venous, diabetic foot, or pressure ulcers) is on the rise, reaching epidemic proportions, which justifies the increased interest in finding more efficient therapies. and stem cell therapies for wound healing. New insights in the field of nanotechnology-based targeted delivery of therapeutic agents for wound healing are also featured.
■ NANOTECHNOLOGY IN WOUND HEALING
An increasing number of innovative nanotherapies have emerged in the field of wound healing and are currently under clinical investigation (Table 2) . Various nanoscale strategies were explored for targeting different phases of wound repair (Figure 2 ), including nanomaterials. There are two main categories of nanomaterials used in wound healing: (1) nanomaterials that exhibit intrinsic properties beneficial for wound treatment and (2) nanomaterials employed as delivery vehicles for therapeutic agents. 20, 34 ■ NANOMATERIALS AS INTRINSIC THERAPEUTIC AGENTS Metallic and Metal Oxide Nanomaterials. Silver is best known for its antibacterial effect mediated through the blockage of respiratory enzyme pathways and alteration of microbial DNA and the cell wall. 60 The advantage of using silver for wound healing is that it is effective against multiresistant and biofilm-forming bacteria. 47, 61, 62 Chronic wounds are characterized by bacterial biofilms, bacterial communities enclosed in a protective self-produced extracellular polymeric substance. 63 Wound-associated biofilms have been shown to induce apoptosis, release of reactive oxygen species and inflammatory cytokines, contributing to chronic inflammation and inhibition of re-epithelialization. 2, 64, 65 Moreover, microorganisms within biofilms represent a therapeutic challenge due to their persistent nature and resistance to conventional antimicrobial therapy. 66, 67 Silver compounds such as silver nitrate and silver sulfadiazine are extensively employed to treat chronic wound and burn infections. 68, 69 However, these compounds, especially silver sulfadiazine, might result in tissue toxicity. To circumvent this drawback, silver nanoparticles with high surface-to-volume ratio were synthesized which rendered these materials more efficient at low concentrations, thus resulting in reduced toxicity in comparison to traditional silver compounds. 69 It was demonstrated that pure silver nanoparticles were able to treat inflammation through cytokine modulation and induce wound healing with decreased scar formation. 35 Different shapes and sizes of silver nanostructures were also investigated and shown to achieve different degrees of antibacterial activity. 70 Kelestemur et al. demonstrated that surface modification of silver nanoparticles with the thiolated oligonucleotide (5′-HS-(CH 2 ) 6 -TAATGCTGAAGG-3) reduced the cytotoxic effect by prolonging the release of silver ions. 71 Another form of silver, nanocrystalline silver, is also considered beneficial due to its efficiency in releasing aggregates of silver nanoparticles that can cover large wound surface area. 36 Nanocrystalline silver dressings like Acticoat provided sustained release of Ag + , thereby overcoming the potential consumption of silver by interaction with target cells or inactivation by protein and anion complexes in the wound fluid. 36 Nevertheless, the use of silver-based nanomaterials for wound healing still suffers from drawbacks such as blue-gray coloration of the skin upon prolonged use, and reoccurrence of silver-resistant bacteria. 72−74 The intrinsic antibacterial properties of zinc oxide nanoparticles (nZnO) prompt the use of these nanomaterials in several hydrogel-based wound dressings. 75, 76 nZnO are less toxic to mammalian cells than silver nanoparticles, which makes these nanoparticles a suitable choice as an inorganic antibacterial agent. 77, 78 In a recent study, nZnO were introduced into a microporous chitosan hydrogel bandage. 75 The prepared composite bandage had a high swelling ability that allowed the absorption of wound exudates, resulting in activation of platelets and blood clotting. In vivo studies demonstrated that the bandage possessed essential antibacterial properties and cytocompatibility as it promoted re-epithelialization and collagen deposition. In another study, ZnO nanoflowers (flower-like morphology of ZnO nanostructures) exhibited a proangiogenic activity, which was confirmed by in vitro and in vivo assays. 40 However, despite the high potential of metallic nanoparticles in treating drug-resistant bacteria, these materials possess high toxicity, thus limiting their use in wound healing. 79 Nonmetallic Nanomaterials. Carbon-based nanomaterials have been proposed for wound-healing applications. Carbon fullerenes exhibit interesting properties that offset several pathological mechanisms responsible for obstructing the wound-healing process. 80 Some fullerene derivatives have demonstrated antioxidant and anti-inflammatory properties, which designates these materials as therapeutic agents for wound healing. 80 A recent study reported the use of graphene oxide (GO) nanosheets for photothermal treatment of bacterial and fungal wound infection. 81 A synergistic effect against different pathogens was elicited by action of GO and the heat generated from the irradiation of these nanomaterials with a near-infrared Nd:YAG laser. The application of the laser and GO resulted in a faster healing of infected wounds, yielding a noninvasive alternative to antibiotic treatment.
Polymeric nanoparticles, specifically naturally occurring polymers like chitosan nanoparticles, have been studied for their antibacterial activity and pro-wound-healing properties. 32 Polymeric nanomaterial therapy involves the use of polymeric materials as dressings or as delivery vehicles. 20 The natural polymer chitosan was selected as a dressing material because of its biocompatibility, biodegradability, hemostatic activity, and antibacterial properties. 42 Chitosan composites usually exhibit unique properties that are not individually displayed by chitosan or the incorporated materials.
82
■ NANOSTRUCTURES AS CARRIERS OF THERAPEUTIC AGENTS Nitric Oxide Containing Nanocarriers. The nitric oxide free radical is one of the several intrinsic pro-wound-healing agents. 83 The highest NO synthase (NOS) activity is observed during the early phases of wound healing when NO is synthesized by inflammatory cells. 84, 85 NO plays an important role in inflammation, cellular proliferation, ECM matrix deposition, angiogenesis, and matrix remodeling. 23,86−88 Moreover, NO is an antibacterial agent effective against a broad range of bacteria, including biofilm forming microorganisms, through an oxidation process involving free radical superoxide (O 2 * − ) to form peroxynitrite (−OONO). Several studies investigated the controlled release of NO using nanoscale delivery systems. An optimal NO delivery system should have high loading capacity, prolonged time release, and low cytotoxicity. 89, 90 To that end, a pH-and light-responsive gatekeeper system was designed to modulate a spatiotemporal NO release for corneal wound-healing application. 90 In another study, NO-releasing poly(lactic-co-glycolic acid) (PLGA)−polyethylenimine (PEI) nanoparticles were synthesized for assessment of healing activity in methicillin-resistant Staphylococcus aureus (MRSA) infected wounds. 89, 91 The system allowed for a sustained and prolonged NO release due to the incorporation of PEI/diazeniumdiolate (NONOate) into the hydrophobic PLGA nanoparticle matrix and inhibition of the NONOate group degradation. The antibacterial activity of the designed nanoparticles was complemented by the enhanced wound healing observed upon treating various skin infections with these nanoparticles.
Antibiotics-and Antioxidant-Containing Nanoparticles. Chen et al. functionalized gold nanodots with antimicrobial peptides, known as natural antibiotics, in order to inhibit the growth of drug-resistant bacteria and promote healing in a rodent wound model. 92 In this system, the cyclic lipopeptide surfactin (SFT) self-assembled on gold nanodots by hydrophobically interacting with 1-dodecanethiol (DT) molecules that cap gold nanodots. The nanoparticles exhibited much higher antibacterial potency against Gram-negative and Grampositive bacteria than free SFT. The enhanced inhibitory effect compared to the peptidic antibiotic alone was due to the ability of the designed nanoparticles to disintegrate the bacterial membrane. In an attempt to heal diabetic ulcer wounds, gold nanoparticles (AuNPs) were combined with the antioxidants epigallocatechine gallate (EGCG) and α-lipoic acid (ALA). 43 These nanoparticles accelerated healing by regulating inflammation and angiogenesis. In addition, the application of AuNPs to the wounds allowed for an increase in the skin absorptivity of the nanoscale mixture.
The delivery of curcumin (CC) or diferuloylmethane via different types of nanomaterial-based vehicles has been investigated in wound healing given its antibiotic, antioxidant, and anti-infective properties. 93 CC plays a major role in the proliferative phase of wound healing by increasing the granulation tissue and promoting the biosynthesis of several components of the ECM. 94, 95 Curcumin has also been encapsulated within a highly structured porous lattice of silane composite nanoparticles. 96 The use of this nanoparticle matrix enabled topical delivery and controlled release of the drug overtime, thereby limiting curcumin's degradation, increasing its bioavailability, and enhancing its performance for the treatment of infected burn wounds.
The majority of these nanoparticle carriers have been used for the delivery of therapeutic agents with antibacterial properties; nonetheless, other nanosystems such as solid lipid nanoparticles and liposomes were explored as nanocarriers of wound-healing drugs, chosen based on the needs of the wound. 97 For example, liposomes were recently used to facilitate the delivery of madecassoside drug in order to promote cell growth, accelerate cutaneous wound healing, and reduce scar formation. 98 ■ NANOENGINEERED SCAFFOLDS FOR WOUND HEALING One significant aspect of the current therapeutic agents employed in wound healing involves engineering of nanopolymeric scaffolds to mimic the properties of ECM, i.e., its fibrous nature and nanoscale features. Several nanotechnology It was demonstrated that pure silver nanoparticles were able to treat inflammation through cytokine modulation and induce wound healing with decreased scar formation.
techniques are used for the formation of scaffolds, including electrospinning, self-assembly, and phase separation ( Figure 3 ). Among these methods, electrospinning is the primary choice for nanofiber fabrication. 32, 51 Electrospinning is a wellestablished technique for engineering porous polymeric nanofibers, which has proven successful in generating nanoscaffolds that demonstrate physical and structural properties analogous to those of the ECM. 99 Electrospun nanofibers derived from a combination of PLGA/silk fibroin SF were used as hybrid scaffolds to promote attachment and proliferation of fibroblasts for improved healing of diabetic wounds. 48 Dendrimers (highly branched polymers with nanoscale dimensions) with anti-inflammatory properties were also incorporated into wound dressings. 100 For instance, gelatin−dendrimer nanofibers were generated via electrospinning and treated the blends with polyethylene glycol (PEG) to form semi-interpenetrating networks (sIPNs). 101 Silver was incorporated within the sIPNs network to add antibacterial properties to the network.
The nanotopography of a wound dressing scaffold has been the focus of interest of researchers aiming at minimizing scar formation while maintaining a high rate of wound closure. 103 In this regard, silicon wafers with different polystyrene nanogroove patterns were designed to study cell adhesion and migration behavior for enhancement of wound closure. 104 The 600 nm pitch grooves produced an enhanced initial osteoblast adhesion and a directional cell migration parallel to the grooves. 104 Further work demonstrated that the orientation and density of nanogrooves are crucial for fibroblast migration during wound healing. 103 Scale patterns of a few micrometers and a few hundred nanometers were also fabricated and contrasted to determine cell migration speed. The study showcased that geometrical nanotopography factors can alter the cell migration speed, division, ECM production, and proliferation rate, 103 thus highlighting the importance of the nanotopography of the scaffold in wound healing.
■ GROWTH FACTOR INCORPORATED NANOMATERIALS
Growth factors play a pivotal role in modulating and coordinating cellular processes during all phases of wound healing (Figure 1) . 105, 106 In addition to (FDA-approved) rhPDGF, many growth factors were brought for testing in patients, including recombinant human epidermal growth factor (rhEGF) and recombinant human vascular endothelial growth factor (rhVEGF). 16, 107, 108 Although rhEGF has been shown to accelerate wound closure in patients, there is not enough evidence to support FDA approval at this time due to lack of large randomized controlled trials. Recombinant human fibroblast growth factor (rhFGF) has also been explored due to its beneficial effects on fibroblasts, which are crucial for proper wound bed restoration and ECM deposition. 109 Major hurdles in designing growth factor therapy approach are protecting growth factors from enzymatic degradation in the proteolytic wound environment and achieving sustained release. Thus, formulations using nanoscale systems have been prepared. 32 PLGA nanoparticles were used to deliver rhEGF to enhance the closure of full-thickness diabetic wounds. 110 A sustained release of this growth factor was also achieved by incorporating it into chitosan nanoparticles within a fibrin gel. The encapsulation of rhEGF made it stable and assisted in keeping its bioactivity in simulated wound environments. 111 Furthermore, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were developed for the sustained and effective release of rhEGF. The topical administration of rhEGFloaded lipid nanoparticles was successful in terms of the encapsulation efficiency and increased rate of wound closure, in vivo. 112 The growth factor rhVEGF has also been investigated for its application in wound healing due to its ability to promote angiogenesis. 113 A hybrid composite of PLGA nanoparticles embedded in chitosan−poly(ethylene oxide) nanofibers was employed for the release of dual growth factor VEGF and PDGF. 114 This nanoparticle-in-nanofiber system delivering both growth factors enhanced wound healing in vivo through VEGFpromoted angiogenesis and PDGF-mediated tissue regeneration and remodeling (Figure 4) . A synergistic effect against different pathogens was elicited by action of GO and the heat generated from the irradiation of these nanomaterials with a nearinfrared Nd:YAG laser.
Although highly promising in preclinical animal studies and small clinical trials, success of growth factor therapy has been so far hampered by the highly proteolytic chronic wound environment, 4 which may be effectively addressed by nanotechnology-based design with incorporated protease inhibitors. However, multiple studies have shown downregulation of the corresponding growth factor receptors and signaling molecules in chronic wound tissue, limiting their applications. 8, 115 ■ GENE, RNA INTERFERENCE (RNAI), AND SMALL
INTERFERING RNA (SIRNA) NANOTHERAPIES
Gene-activated matrix therapy, which combines gene therapy and tissue engineering, has evolved as a means to increase or knock down the expression of a target gene responsible for regeneration of bone, cartilage, and skin. 116 The advantage of using gene therapy for wound healing is the stability of DNA as compared to growth factor therapy. 116, 117 Naked and colloidal DNA have been delivered to wound sites by direct injection, gene gun, and electroporation. However, these techniques suffer from the need for repeated injections as well as inconsistent and short-term gene expression. 117 These issues can be overcome by use of electrospun nanofibrous meshes as matrices for gene encapsulation and wound dressing material. Nucleic acids have been impregnated into these nanofibers to enhance tissue regeneration and eventually decrease scar formation in normal and diabetic wounds. 117 More recently, electrospun scaffolds of a blend of poly(lactic acid) (PLA) and PCL were fabricated for localized delivery of DNA plasmid encoding for keratinocyte growth factor. 54 The polyester scaffolds have also been shown to be a good option for treatment of cutaneous wounds. 54, 118 RNAi therapy permits silencing gene expression by selectively targeting molecules overexpressed in the chronic wound environment such as matrix metalloproteinases (MMP)s ( Figure 5) . 118, 119 Nanoparticle-based technology was implemented to protect the targeted delivery of siRNA from potential degradation of this effector molecule by intracellular RNases.
120 A (MMP)-2 siRNA-incorporated linear polyethylenimine (LPEI) complex was immobilized onto a nanofibrous mesh via MMP cleavable peptides allowing for controlled release. 121 This system efficiently suppressed MMP-2 levels and promoted wound healing in diabetic murine wounds. Spherical nucleic acid (SNA) gold nanoparticle conjugates have been also used for efficient siRNA delivery in vivo. 55 A duplexed ganglioside-monosialic acid 3 synthase (GM3S) thiolated siRNA was attached to 13 nm diameter gold nanoparticles in order to engineer the GM3 SNA construct. The designed RNAi-based gene regulator, GM3S SNA, was capable of accelerating keratinocyte migration and proliferation by depleting the ganglioside GM3S and, consequently, accelerating wound healing in type 2 diabetic wound model. The key role of SNA nanotechnology is the ability of the SNAs to pass through the epidermal barrier, permitting topical therapeutic application. However, there is still a need for newer, more efficient, and refined RNAi-based technologies for wound healing. These technologies should be able to overcome the limitations of current RNA delivery by incorporating selective targeting and better retention, effectiveness, bioavailability, and safety, in addition to addressing the issues associated with this type of therapy in the presence of wound bacteria.
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■ STEM CELL INCORPORATED NANOSCAFFOLDS
Therapeutic approaches involving stem cells (SC) have been investigated extensively for chronic wounds and shown to facilitate re-epithelialization and promote angiogenesis. 123 Bone marrow derived mesenchymal stem cells (BM-MSCs), umbilical cord derived MSCs, adipose-derived stromal cells (ASCs), placenta-derived stem cells, bone marrow derived mononuclear cells (BM-MNCs), and bone marrow derived endothelial progenitor cells have all been highlighted as having therapeutic potential for wound-healing disorders. 123−126 It is not fully clear what is the potential mechanism of action; however, it is believed that stem cell therapies provide a dynamic microenvironment (targeting multiple cell types simultaneously) through paracrine effects in order to facilitate process of healing. 127−129 Direct delivery of MSCs to the wound can induce rapid cell death, and attempt of attenuation of this effect have been proposed by bioengineering of the therapeutic delivery platform. 130 Current applications of SCs include local delivery to wounds using dressings, sprays, injections, and systemic administration. Nanotechnology-based approaches were explored to generate a nanomatrix with tailored biophysical properties to better control the differentiation of stem cells. An interesting strategy for use of MSCs is based on the production of nanoscaffolds that mimic the physical characteristics of human skin. 131, 132 The incorporation of SCs into this nanoscaffold resulted in an engineered wound dressing holding a "cocktail" of stem cells, growth factors, and the matrix itself. 129, 133 Polymeric nanofibers also had a recent surge in the tissue regeneration field. These nanofibers are biomimetic and can simulate native tissue, making for an ideal stem cell niche. BM-MSCs were attached to a collagen/PLGA nanofiber scaffold and demonstrated the ability of the nanoscaffold to secure a faster closure of cutaneous wounds. 58 The surface nanotopography of the fibers, the presence of collagen, and the chemical conjugation of a CD29 antibody that will bind to CD29 antigen overexpressed on MSCs surface contributed to an enhanced stem cell adhesion. The nanoscaffold/BM-MSC composite was shown as a useful approach for wound healing and skin generation in acute full-thickness skin wounds. Despite significant advancements, no stem cell therapy for the treatment of chronic wounds has yet acquired FDA approval for efficacy. 123 Viable treatments will likely use stem cells in accordance with other local and systemic therapies.
■ NANOTECHNOLOGY-BASED TARGETED DELIVERY TO ACHIEVE CELL-TYPE SPECIFICITY Targeted delivery of nanomaterials for wound-healing applications is still scarce in comparison to other nanotechnologies. Achieving targeted delivery of therapeutics is significant to improve efficacy, reduce any harmful side effects on the nontarget tissues, and reduce cost of therapy. 120 A few known examples of targeted wound-healing therapeutics are discussed below.
Targeted delivery of the stromal cell derived factor 1 (SDF-1) to the wound site was performed by developing ROS stimulus responsive polymeric nanoparticles as delivery vehicles for SDF-1. 134 The chemokine SDF-1 is involved in the migration of BMSCs to the sites of injury and subsequent induction of wound vascularization, which makes the presence of SDF-1 necessary for the stem cell based treatment of wound repair. The nanoparticles were composed of a biodegradable polymer poly(1,4-phenyleneacetone dimethylene thioketal), PPADT, that depolymerizes in the presence of a high concentration of ROS. Hence, the delivery of the macromolecular drug SDF-1 via the polymeric nanoparticles enhanced its bioavailability and provided a localized and specific targeting of the wound site. The intravenously injected nanoparticles were able to advance the healing of full-thickness wounds in mice.
To date, the only example of targeted nanocarrier-mediated delivery of stem cells was designed by our team to achieve homing of the cells to the sites. 135 This study demonstrates the competency of nanotechnology in overcoming the limitation associated with systemic stem cell therapy, which is the low number of viable cells that home to the target tissue. In this work, acetylated polyamido amine (PAMAM) dendrimeric nanocarriers armed with cellular molecular recognition moieties were used to coat BMC and MSC. The recognition molecule, typically a small peptide or protein, soluble part of E-selectin (sE-sel) that has a binding counterpart in the site of interest, was meticulously chosen to adhere to a receptor (CD44, SDF-1, I-CAM, P-CAM, etc.) highly overexpressed on the endothelium of wound bed capillaries, thus acting like a GPS to direct the cell complex with the surrounding nanocarriers to the site of injury. This nanocarrier-targeted delivery platform demonstrated biocompatibility and high efficiency of the designed nanocarriers to direct stem cells to the injured tissues, the eye and a dorsal wound, while enhancing the proangiogenic and prorepair functions of the cells without any toxicity or immunogenic effects ( Figure 6 ). This nanocarrier platform is versatile as it can be tailored for the specific delivery of DNA, siRNA, small drugs, proteins, and cells to any location in the body by complexing the therapeutic agent to the dendrimer nanoparticle and choosing the right molecular recognition molecule to integrate within the nanoparticle.
Another approach that has been undertaken for targeted delivery is based on functionalization of lipid nanoparticles (LPNs) for restoration of oxidative metabolism in chronic ischemic wound edge tissue. 136 AntihypoxamiR functionalized gramicidin LPNs (AFGLN nanostructures) were synthesized and loaded with a locked nucleic acid (LNA) based anti-miR-210 power inhibitor (AFGLN miR-210 ). The intradermal delivery of AFGLN miR-210 to ischemic wounds accelerated re-epithelialization, as the inhibition of hypoxamiR miR-210 is associated with maintaining keratinocyte cell proliferation. The advantage of the AFGLN design is that it is formulated using components previously approved by the FDA for human applications. 136 
■ UNMET NEEDS AND FUTURE DIRECTIONS
Although more than seven million Americans are affected by chronic wounds annually, current research has shown limited success to produce more than a handful of therapeutic agents deemed efficacious by the FDA. Given the complexity of the chronic wound pathology and tissue repair process, it is not surprising that current therapeutic approaches failed to accumulate enough evidence in order to acquire FDA approval, which raises the need for alternative therapeutic approaches that are deemed viable and efficient for treatment of nonhealing wounds. There are several contributing elements that impede more rapid development of therapies for patients with chronic wounds including limited knowledge in understanding pathophysiology in patients; variability of patient population and comorbidities at the individual level (patient-to-patient) and the group level (diabetic foot to venous leg to pressure ulcers); complexity of clinical trial design and associated costs; alternative clinical end points; and lack of public awareness.
The major challenge remains in developing appropriate combinational therapy able to target multiple dysfunctional cellular processes and identifying the optimal timing for delivery of each therapeutic agent. However, we are currently in the midst of the BD2K (Big Data to Knowledge) initiative whereby computational biomedicine stands to revolutionize medicine. BD2K programs and centers are rapidly developing tools and "ecosystems" for integration of large data sets, such as medical records, genomics, and genotyping with drug customization, or drug response data that may be accessible to public domains. One can envision a near future in which tailored therapies will be based on unique phenotype−genotype characteristics. This will provide major opportunities to adapt existing and create new nanotechnology approaches that will streamline and facilitate individualized treatment plans that arise from such platforms.
The emergence of various nanotechnologies, especially multifunctional systems, in wound healing is showcased by the high number of publications witnessed in recent years, which indicates the high expectations toward nanotherapeutic interventions in the wound-healing field. However, the hurdle lies in gathering enough information about the physicochemical properties of the nanoscale systems and their anticipated behavior and toxicity in the human body. In addition, the high purity of the scaffolds and nanoparticles mandated by the FDA for human use is also a challenge, as often the bulk preparation and purification of the polymers and nanoparticles prepared are not easy. Thus, there is an incessant need for better synthetic tools and analytical methods that will allow for the translation of nanotechnology-based approaches to the clinic. Extensive efforts are also vital to arm chronic wound therapies with site-specificity The nanotopography of a wound dressing scaffold has been the focus of interest of researchers aiming at minimizing scar formation while maintaining a high rate of wound closure.
and targeting efficiency in order to avoid undesirable events and interferences that might hinder the nanosystems from their biological functions in the human body. In the long term, further studies are indispensable to provide insights into how research findings about nanotechnologybased therapies can be applied in the clinical arena. It is expected that new and exciting nanotechnology platforms will arise; thus, additional research on these technologies is needed to develop international standards on biocompatibility and toxicology of nanotherapies. Overall, the current capabilities in advanced manufacturing and development of various nanosystems, together with the knowledge of chronic wounds, molecular pathology, and phenotype−genotype characteristics, with the help of BD2K, are projected to promote the design of the next generation of wound-healing nanotechnologies.
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